| | The head of the U.S. House of Representative's oversight panel on Wednesday called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of "apparent efforts to stonewall" the probe. | |
| Deodorant not enough to stop your body odor? A new futuristic-style bodysuit with live bacteria embedded in it could help combat those unpleasant smells. | |
| AstraZeneca has made further headway in the race with larger competitor GlaxoSmithKline's to use a promising new class of drugs to treat ovarian cancer. | |
| Scientists are a step closer to being able to cure the deadly Ebola hemorrhagic fever after two experimental drugs showed survival rates of as much as 90% in a clinical trial in Congo. | |
| (Reuters Health) - Adolescents and young adults who have smoked e-cigarettes are more than three times more likely to move on to marijuana than youth who never try vaping, a research review study suggests. | |
| (Reuters Health) - More than half of key hospital doctors in England who would likely be involved in responding to a major incident, such as a bombing or massive fire, are ill prepared for it, a new report suggests. | |
| (Reuters Health) - Parents who smoke may be more likely to quit when they receive tobacco screening and smoking cessation treatment from their child's pediatrician than when they don't get this support, a new study suggests. | |
| An intervention used to treat astronauts has relevance for people on the ground with medical conditions that cause repeated fainting, researchers say. | |
| Canada's patented drug price regulator, set to gain new powers next year, may be "more forgiving" in setting price caps for drugs that treat rare diseases, the agency's executive director told Reuters, as some advocates warned the country's pricing reforms would hurt patients. | |
| Deciphera Pharmaceuticals Inc's shares more than doubled on Tuesday after the drugmaker said its treatment helped stomach cancer patients live longer without their disease worsening in a late-stage study. | |
| U.S. Senate Finance Committee Chairman Chuck Grassley has asked Swiss drugmaker Novartis AG to provide details on data manipulation related to its $2 million gene therapy, Zolgensma, by Aug. 23. | |
|
| |